Adverum Biotechnologies

$1.41 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Adverum Biotechnologies

Adverum Biotechnologies, Inc. operates as a biotechnology company. The Company focuses on targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, and wet age-related macular degeneration.

Stock Analysis

last close $1.47
1-mo return -15.5%
3-mo return 61.8%
avg daily vol. 1.01M
52-week high 2.57
52-week low 0.8
market cap. $145M
forward pe -
annual div. -
roe -44.4%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 65.4%
baraka

Subscribe now for daily local and international financial news

Subscribe